EUCTR2021-005238-40-IT进行中（未招募）1 期
A phase 2 study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer. -
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •1. Is capable of giving signed informed consent. This includes compliance with the requirements and restrictions listed in the study informed consent form (ICF) and in this protocol.
- •2. Must be at least 18 years of age, or the legal age of consent in the jurisdiction in which the study is taking place, at the time of giving signed informed consent. Type of Participant and Disease Characteristics
- •3. Has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor-positive breast cancer by local laboratory.
- •4. Breast cancer is also HER2-negative and advanced (locoregionally recurrent; not amenable to curative therapy, eg, surgery and/or radiotherapy; or metastatic) and meets one of the following criteria:
- •Newly diagnosed advanced/metastatic breast cancer, treatment-naïve.
- •Relapsed with documented evidence of relapse following neoadjuvant (adjuvant) endocrine therapy, with no treatment for advanced/metastatic disease.
- •Relapsed with documented evidence of relapse following completion of adjuvant endocrine therapy, then subsequently progressed with documented evidence of progression after one (1) line of endocrine therapy (with either tamoxifen or an AI) for advanced/metastatic disease.
- •Newly diagnosed advanced/metastatic breast cancer at diagnosis that progressed with documented evidence of progression after one (1) line of endocrine therapy (with either tamoxifen, exemestane, or an AI [other than fulvestrant]).
- •Please refer to the Protocol for further inclusion criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical Conditions
- •1. Has symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy, per the Investigator's best judgment.
- •2. Has peritoneal carcinomatosis.
- •3. Has inflammatory breast cancer at Screening.
- •4. Has central nervous system (CNS) involvement, unless participant is at least 4 weeks from prior therapy completion to starting study treatment, has stable CNS tumor at the time of Screening, and is not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases.
- •5. Has any clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
- •Please refer to the Protocol for further exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patientsAdvanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïveCohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenanceMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003083-98-HUEllipses Pharma Limited384
进行中（未招募）
1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patientsEUCTR2020-003083-98-GBEllipses Pharma Limited384
进行中（未招募）
1 期
A study assessing the efficacy and safety of an investigational drug called fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsEUCTR2020-002858-24-SEClementia Pharmaceuticals Inc, an Ipsen Company98
尚未招募
2 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsNL-OMON54489Ipsen Pharmaceuticals5
招募中
2 期
A study assessing the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for FOPfibrodysplasia ossificans progressivaJPRN-jRCT2041220080egar Karimian4